APAC IPOs & Placements, Aequitas Research

Clarence Chu

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Shukun (Beijing) Technology / Equity Capital Markets

Shukun (Beijing) Technology (1702626D CH)

<p><a href="https://www.smartkarma.com/entities/shukun-beijing-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:34403:1" rel="noopener">Shukun (Beijing) Technology Co., Ltd. (1702626D CH)</a> is looking to raise about US$300m in its upcoming Hong Kong IPO. The deal will be run by JPM, BofA, and BOCI.</p><p>Shukun Technology is a healthcare company that employs AI technology to assist treatment. Its AI-powered Digital Doctor analyses medical imaging data and assists doctors in disease screening, diagnosis and therapy selection. As of the latest practicable date (15 Sept 2021), its DigitalDoc portfolio included 12 products and 25 product candidates covering five critical therapeutic areas, including heart, brain, abdomen, chest and musculoskeletal system. The firm’s DigitalDoc products have been adopted by over 1,200 hospitals in China, including approximately 80% of the Top 100 Hospitals and over 30% of all Class III Grade A hospitals.</p>

Shukun (Beijing) Technology Co., Ltd. (1702626D CH) is looking to raise about US$300m in its upcoming Hong Kong IPO. The deal will be run by JPM, BofA, and BOCI.Shukun Technology is a healthcare company that employs AI technology to assist treatment. Its AI-powered Digital Doctor analyses medical imaging data and assists doctors in disease screening, diagnosis and therapy selection. As of the latest practicable date (15 Sept 2021), its DigitalDoc portfolio included 12 products and 25 product candidates covering five critical therapeutic areas, including heart, brain, abdomen, chest and musculoskeletal system. The firm’s DigitalDoc products have been adopted by over 1,200 hospitals in China, including approximately 80% of the Top 100 Hospitals and over 30% of all Class III Grade A hospitals.

Shukun (Beijing) Technology

Shukun Technology Pre-IPO Tearsheet